Article

Nature and Frequency of Bisphosphonate-Associated Osteonecrosis of the Jaws in Australia

University of Adelaide, Tarndarnya, South Australia, Australia
Journal of Oral and Maxillofacial Surgery (Impact Factor: 1.28). 04/2007; 65(3):415-23. DOI: 10.1016/j.joms.2006.10.061
Source: PubMed

ABSTRACT The purpose of this study is to estimate the frequency and describe the clinical characteristics of patients diagnosed with bisphosphonate-associated osteonecrosis of the jaws (ONJ) in Australia.
Cases of ONJ were identified in 2004 and 2005 primarily by a postal survey of Australian Oral and Maxillofacial Surgeons (OMS) with additional cases from other dental specialists and the Commonwealth of Australia Adverse Drug Reaction Committee (ADRAC). The clinical characteristics were recorded. The frequency of ONJ cases was estimated from prescription and dental extraction data. Univariate and bivariate statistics were calculated.
One hundred fifty-eight cases of ONJ were identified. These were primarily in patients with bone malignancy (72%) and the main trigger was dental extraction (73%). The reported number of cases varied between different Australian States with the highest frequency being reported in the States with the best integrated health systems. The frequency of ONJ in osteoporotic patients, mainly on weekly oral alendronate was 1 in 2,260 to 8,470 (0.01% to 0.04%) patients. If extractions were carried out, the calculated frequency was 1 in 296 to 1,130 cases (0.09% to 0.34%). The total dose of oral alendronate at the onset of ONJ was 9,060 (+/-7,269) mg. The frequency of ONJ for Paget's disease cases was 1 in 56 to 380 (0.26% to 1.8%). If extractions were carried out, the calculated frequency of ONJ was 1 in 7.4 to 48 (2.1% to 13.5%). The frequency of ONJ in bone malignancy cases, treated with mainly intravenous zoledronate or pamidronate was 1 in 87 to 114 (0.88% to 1.15%). If extractions were carried out, the calculated frequency of ONJ was 1 in 11 to 15 (6.67% to 9.1%) The total dose of pamidronate was 3,285 (+/-2,530) mg and zoledronate 62 (+/-54.28) mg at the onset of ONJ. The median time to onset of ONJ was 12 months for zoledronate, 24 months for pamidronate, and 24 months alendronate.
Before the prescription of bisphosphonates for bone disease the patient should be made dentally fit so that the need for subsequent dental extractions is minimized. Appropriate informed consent for the risk of ONJ for different bisphosphonates, for osteoporosis, and malignancy both in general and in particular for dental extractions can be provided using this data.

Download full-text

Full-text

Available from: Brian Neil Stein, Aug 12, 2014
0 Followers
 · 
219 Views
  • Source
    • "Clinical reports describe surgical dental treatments in patients receiving BP treatment as being associated with osteonecrosis of the jaw (ONJ) [8] [9] [10]. ONJ occasionally causes worsening of the quality of life and general status because of unbearable pain and eating dysfunction, but the role of BPs in this mechanism is unknown [11] [12]. However, with regard to the correlation of ONJ incidence with BP potency, it appears that inhibition of osteoclast function and differentiation may be a key factor in the underlying pathomechanism [13]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Bisphosphonates (BPs) are widely used in the prevention of skeletal-related events (SRE), including osteoporosis, skeletal metastases of malignant tumours, and multiple myeloma. Osteonecrosis of the jaw (ONJ) is frequently reported as a major adverse effect induced by BP treatment. The receptor activator of the nuclear factor kappa-B ligand (RANKL) inhibitor, denosumab, has recently been used to prevent SRE, but the frequency of ONJ induced by denosumab is similar to that by BPs. This finding suggests that the inhibition of RANKL-mediated osteoclastogenesis may have a close relationship with the occurrence of ONJ. We therefore investigated the expression status of RANKL-inducible genes in zoledronate-treated mouse osteoclast precursor cells. The molecular targets of zoledronate in the RANKL signal pathway and additional factors associated with osteoclastogenesis were analysed by genome-wide screening. Microarray analysis identified that among 31 genes on 44 entities of RANKL-inducible genes, the mRNA expression level of two genes, i.e., nuclear factor of activated T-cells c1 (NFATc1) and carbonic anhydrase 2 (CAII), was decreased in zoledronate-treated cells. Subsequent analyses verified that these two genes were significantly silenced by zoledronate treatment and that their expression was restored following inhibition of zoledronate action by geranylgeraniol. Zoledronate inhibited RANKL-induced osteoclast differentiation by suppression of NFATc1 and CAII gene expression. Our results suggest that these genes might be common targets for zoledronate and denosumab in the mechanism underlying RANKL-induced osteoclast differentiation. A clear understanding of the common molecular mechanisms of bone-remodelling agents is thus essential for prevention of ONJ.
    Archives of Oral Biology 04/2015; DOI:10.1016/j.archoralbio.2014.09.012 · 1.88 Impact Factor
  • Source
    • "It has been estimated that ONJ occurs in about 20% of patients taking intravenous bisphosphonates; however, the percentage decreased to less than 0.05% in patients taking oral bisphosphonates (between zero and 0.04%). The percentage slightly increased if extractions were carried out (Mavrokokki et al., 2007; Edwards et al., 2008). In the UK in 2006, 77 cases of ONJ were reported to be associated with intravenous bisphosphonates compared with 9 cases associated with oral bisphosphonates (Bradford and Airedale NHS, 2007). "
  • Source
    • "Therefore, the possibility of a fundamental difference in basic condition of the two groups could not be excluded. The prevalence of BRONJ is low and jaw necrosis in osteoporosis patients is even less frequent than bone tumor patients with BPs [5]. In the BRONJ study, it is difficult to carry out a randomized, controlled, prospective study with sufficient number of cases. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective This study aimed to analyze the difference in biochemical markers of patients with osteoporosis taking bisphosphonates (BPs) who developed bisphosphonate-related osteonecrosis of the jaw (BRONJ) vs those who did not develop BRONJ.Patients & methodsForty-one BRONJ patients and 76 control patients who had been treated with alendronate or risedronate were investigated. Bone turnover markers [C-terminal telopeptide (CTX) and bone-specific alkaline phosphatase (bALP)] and inflammatory activity markers [erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) level] were evaluated. In BRONJ patients, radiographic severity and its relation with the serological data and BRONJ staging were analyzed.ResultsCTX and bALP level after the long-term BPs treatment in the control patients was similar to the level of the BRONJ patients at the time of diagnosis. The BRONJ patients showed a significantly higher ESR than the control patients with BPs. BRONJ score were not correlated with CTX and bALP. The severity of BRONJ in alendronate-treated group was strongly correlated with ESR and CRP.Conclusions Bone turnover markers such as serum CTX level has limitation in reflecting BRONJ status. Increased level of inflammatory markers in BRONJ patients implies the importance of inflammation in BRONJ progression.
    04/2013; 25(2):123–128. DOI:10.1016/j.ajoms.2012.06.007
Show more